Author

Maria Jung

Observed name: Jung, Maria

Observed institution: University Hospital Bonn

OpenAlex ID: A5014265990

The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer

2015 · Heidrun Gevensleben, Dimo Dietrich, et al. · Clinical Cancer Research · 234

Improved PCR Performance Using Template DNA from Formalin-Fixed and Paraffin-Embedded Tissues by Overcoming PCR Inhibition

2013 · Dimo Dietrich, Barbara Uhl, et al. · PLoS ONE · 153

PDF

Performance Evaluation of Kits for Bisulfite-Conversion of DNA from Tissues, Cell Lines, FFPE Tissues, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine

2014 · Emily Eva Holmes, Maria Jung, et al. · PLoS ONE · 147

PDF

Diagnostic and Prognostic Value of SHOX2 and SEPT9 DNA Methylation and Cytology in Benign, Paramalignant and Malignant Pleural Effusions

2013 · Dimo Dietrich, Maria Jung, et al. · PLoS ONE · 74

PDF

TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy

2015 · Kasper Drimer Berg, Davide Soldini, et al. · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 51

PDF

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients

2016 · Sebastian Meller, Lisa Zipfel, et al. · Epigenetics · 48

PDF

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies

2016 · Barbara Uhl, Heidrun Gevensleben, et al. · Journal of Molecular Diagnostics · 47

Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites

2016 · Maria Jung, Svenja Pützer, et al. · Clinical Epigenetics · 38

PDF

CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients

2016 · Diane Goltz, Emily Eva Holmes, et al. · Oncotarget · 36

PDF

Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study

2019 · Maria Jung, Jörg Ellinger, et al. · Clinical Chemistry · 34

Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood

2020 · Luka de Vos, Maria Jung, et al. · Journal of Molecular Diagnostics · 28

PDF

DNA Methylation Analysis of Free-Circulating DNA in Body Fluids

2017 · Maria Jung, Glen Kristiansen, et al. · Methods in molecular biology · 28

PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy

2016 · Emily Eva Holmes, Diane Goltz, et al. · Clinical Epigenetics · 20

PDF

Bisulfite Conversion of DNA from Tissues, Cell Lines, Buffy Coat, FFPE Tissues, Microdissected Cells, Swabs, Sputum, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine

2015 · Maria Jung, Barbara Uhl, et al. · Methods in molecular biology · 18

Additional file 2: Table S2. of Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites

2016 · Jung, Maria, PĂźtzer, Svenja, et al. · Figshare

Additional file 1: Table S1. of Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites

2016 · Jung, Maria, PĂźtzer, Svenja, et al. · Figshare

Works count: 20

Citation count: 956

H-index: 14

I10-index: 14